Steve Brody


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Steve Brody is an accomplished trial lawyer who works to advance clients’ business priorities through industry-shaping victories in high-profile litigation while simultaneously protecting clients’ financial and reputational interests with sophisticated media strategies, government and investor relations, and overall crisis management. Steve is Co-Chair of the firm's nationally-recognized Product Liability and Mass Torts Practice, and also works frequently with attorneys in the firm’s Consumer Class Actions, White Collar Defense and Corporate Investigations, and Supreme Court and Appellate Practice Groups. He is the founder and Co-Chair of the firm’s Attorney General Investigations and Litigation Practice.

Steve has defended mass torts, class actions and state attorney general cases involving pharmaceutical and medical device promotion and labeling, consumer fraud, false claims, state Medicaid reimbursement, health insurance plan benefits, and preferred provider agreements, among other issues. As a trial lawyer, he led two of the highest profile US civil trials in the last two decades, State of Oklahoma v. Johnson & Johnson and United States v. Philip Morris. At the federal appellate level, he has recently handled appeals in the Fourth, Sixth, Seventh, Eighth, Ninth, Tenth, Eleventh and DC Circuits, and at the state level in Alabama, Arkansas, California, Louisiana, Maine, Mississippi, Oklahoma, Pennsylvania, New Jersey, South Carolina, Texas, Virginia, Washington, and West Virginia.


Honors & Awards

  • Recommended by Who's Who Legal (WWL) for Product Liability Defence (2023)
  • LMG Life Sciences Product Liability Lawyer of the Year (2021)
  • Law360 Product Liability MVP (2021)
  • Recognized by Chambers USA for Product Liability & Mass Torts (2021-2023)
  • Named a Life Sciences “Trailblazer” by The National Law Journal (2020)
  • Named a Litigation Star (2018), Local Litigation Star (2018-2023), and a National Practice Area Star (2019-2023) for Product Liability by Benchmark Litigation
  • Recommended by The Legal 500 US for Dispute Resolution - Product Liability, Mass Tort and Class Action (2016-present) and General Commercial Disputes (2020-2021)
  • “Life Sciences Star” for Products Liability Litigation and White-Collar/Government Investigations by LMG Life Sciences (2012-present)
  • Recognized in Washington, DC Super Lawyers for Civil Litigation Defense (2013) and Class Actions and Mass Torts (2014-present)
  • Recommended by The Legal 500 US for Healthcare: Life Sciences (2022-2023); Product Liability, Mass Tort and Class Action - Defense: Automative/Transport (2023); Product Liability, Mass Tort and Class Action - Defense: Consumer Products (Inclding Tobacco) (2023); Product Liability, Mass Tort and Class Action - Defense: Pharmaceuticals and Medical Devices (2023); Product Liability, Mass Tort and Class Action - Defense: Toxic Tort (2023); State Attorneys General (2023)


Bar Admissions

  • District of Columbia
  • Virginia

Court Admissions

  • US District Court for District of Columbia
  • US Court of Appeals, District of Columbia, Fourth, Sixth, Seventh, Eighth, Ninth, and Tenth Circuits
  • US Supreme Court


  • Washington & Lee University, J.D., 1994
  • Williams College, B.A., Political Economy, 1990

Professional Activities

Selected Speaking Engagements

  • Moderator, “Lessons Learned From the Opioid Litigation,” Government Investigations & Civil Litigation Institute Annual Meeting (November 7-9, 2022)
  • Panelist, “Opioids, Public Nuisance, and the Evolution of Mass Torts,” New York City Bar Association (May 10, 2022)
  • Moderator, “Attorney General Enforcement Trends,” Government Investigations & Civil Litigation Institute Annual Meeting (October 9-11, 2017)
  • International Association of Defense Counsel Mid-Year Meeting (2015)
  • ABA Environmental, Mass Torts & Products Liability Litigation Committees’ Joint CLE Seminar (2015)
  • ACI Drug and Medical Device Conference (2014)
  • HarrisMartin’s Mass Tort Litigation Conference with Judge Marina Corodemus (Ret.) (2013, 2014)
  • PhRMA Law Section Annual Meeting (2013)
  • ACI 8th Advanced Summit on Off-Label Communications (2012)
  • ACI Expert Guide to Advertising, eMarketing & Promotions for the Pharmaceutical Industry (2011)
  • ACI 7th National Forum on Off-Label Communications (2010)
  • “Defense Perspectives on Attorney General Pharmaceutical Claims,” LexisNexis/HB Litigation Conferences (2008, 2009)
  • “Ethics & Discovery,” Practising Law Institute (2007, 2009-2015 (Chair))
  • In a seven-week televised trial garnering national media attention, defended against the State of Oklahoma's claims in the first case to go to trial against an opioid manufacturer, limiting the State to a trial level judgment of just $465 million of the $17.5 billion it sought and then obtaining a reversal and full defense judgment on appeal
  • Obtained appellate reversal and dismissal of $1.2 billion Medicaid fraud judgment against pharmaceutical manufacturer in action brought by the Arkansas Attorney General
  • Prevailed on appeal from $330 million judgment in Medicaid fraud action by the Louisiana Attorney General, winning reversal and entry of judgment in favor of pharmaceutical manufacturer
  • Defended a $74 million constructive fraudulent conveyance action for a hospital and health systems operator in the US Bankruptcy Court for the District of Columbia in a seven-week bench trial, securing a full defense judgment on all claims that was upheld on appeal to the district court
  • Obtained reversal of $4.5 million consumer fraud judgment against a pharmaceutical manufacturer in a state court action brought by the West Virginia Attorney General

In the News

LMG Life Sciences Awards Americas 2023: Shortlists Announced

八月 25, 2023

Law360: Product Liability Group Of The Year: O’Melveny

三月 2, 2023

The National Law Journal: The 2022 NLJ Awards: Professional Excellence—General Litigation

十月 21, 2022

Expert Guides Best of the Best USA: Steve Brody and Tancred Schiavoni

十月 7, 2022

Law360: Opioid Makers Cement Calif. Win As Judge Spurns Objections

十二月 14, 2021

The American Lawyer: Tried and True: With the World Watching, O’Melveny’s Products Liability Litigators Get Clients the Results they Need.

十二月 3, 2021

Law360: Meet The Attys Repping Travis Scott In Astroworld Litigation

十二月 1, 2021

The American Lawyer: Litigators of the Week: A Huge Win for Drug Company Defendants in California Opioid Trial

十一月 5, 2021

The Recorder: Drug Companies Win Big in Calif. Opioid Trial as Judge Rejects Public Nuisance Claim

十一月 2, 2021

Law360: Drugmakers Not Liable For Calif. Opioid Crisis, Judge Finds

十一月 1, 2021

Press Releases

Alerts and Publications